A sourced history of indicative valuation ranges for ImmunoSource, including the model basis, evidence trail, confidence and limitations.
Company overview0451125125
2024 to 2025
sme public accounts
Jul 28, 2026
€30k – €80k
2 valuation checkpoints · medium confidence · KBO public registry, raw_company_filings
Historical indicative ranges based on public filings. This is not an asking price or confirmation that the company is for sale.
Based on filed company accounts| Fiscal year | Low | High |
|---|---|---|
| 2024 | €40k | €120k |
| 2025 | €30k | €80k |
The historical valuation curve is public. Create a free account for the future five-year growth forecast, the insights behind it, and concrete action points that can increase this company’s value.
Free account · private workspace
Public filings are a starting point. Owner-confirmed accounts, net debt, leases and commercial context can refine the range for a sale, financing or transfer.
You have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
This automated range is indicative only. It is not a certified valuation or financial, investment, tax or legal advice.
Indicative public valuation range based on financial year 2025. This historical record does not yet contain an immutable calculation snapshot, so no sector range is reconstructed after the fact. Not a transaction value, asking price or fairness opinion.
